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Stimulation of innate immunity is increasingly recognized to play an important role in the pathogenesis of alcoholic liver
disease (ALD), while the contribution of adaptive immunity has received less attention. Clinical and experimental data show
the involvement of Th-1 and Th-17 T-lymphocytes in alcoholic hepatitis. Nonetheless, the mechanisms by which alcohol triggers
adaptive immunity are still incompletely characterized. Patients with advanced ALD have circulating IgG and T-lymphocytes
recognizingepitopesderivedfromproteinmodiﬁcationbyhydroxyethylfreeradicalsandendproductsoflipid-peroxidation.High
titers of IgG against lipid peroxidation-derived antigens are associated with an increased hepatic production of proinﬂammatory
cytokines/chemokines. Moreover, the same antigens favor the breaking of self-tolerance towards liver constituents. In particular,
autoantibodies against cytochrome P4502E1 (CYP2E1) are evident in a subset of ALD patients. Altogether these results suggest
thatallo-andautoimmunereactionstriggeredbyoxidativestressmightcontributetohepaticinﬂammationduringtheprogression
of ALD.
1.Introduction
Accordingto theWorldHealthOrganization, alcohol-related
diseases are the third cause of death and disability in most
well-developedcountriesandaleadingcauseofdiseaseinthe
developing countries in Eastern Europe, Central and South
America, and East Asia [1]. Although several organs are in-
jured by ethanol, alcoholic liver disease (ALD) is the most
common medical consequence of excessive alcohol intake
accounting for about 70% of the recorded mortality [2].
Thus,understandingthemechanismsresponsibleforalcohol
liver injury has a relevant clinical and social impact. Current
viewindicatesthatmultiplefactorsincludingoxidativestress,
endoplasmic reticulum stress, metabolic alterations, and in-
terferences with the transduction of intracellular signals are
involved in ALD pathogenesis [3]. Furthermore, emerging
evidence suggests that chronic inﬂammation represents the
driving force in the evolution of alcohol liver injury. In this
context, a large number of studies have investigate the role
of innate immunity in ALD ([4–8] for recent review), while
the contribution of adaptive immunity to alcohol-induced
hepatic inﬂammation has received much less attention. This
paper will give an overview of the possible implications of
adaptive immunity in the inﬂammatory processes associated
with ALD.
Early studies have shown that liver inﬂammatory inﬁl-
trates in alcoholic hepatitis and active alcoholic cirrhosis
contain both CD8+ and CD4+ T-lymphocytes [9]. In
either chronic alcohol-treated mice or alcohol abusers liver-
inﬁltrating T cells express an activation/memory phenotype
and respond to T-cell receptor stimulation by producing Th-
1cytokinessuchasinterferon-γ (IFN-γ)andTNF -α[10,11].
A Th-1 cytokine pattern is also evident in peripheral blood
T cells from active drinkers with or without ALD [12]. In
agreement with these observations, Paronetto [13]r e p o r t e d
the presence in ALD patients of circulating antibodies
targeting alcohol-altered autologous hepatocytes. Hyperpro-
duction of polyclonal gamma globulins is also frequent in al-
cohol abusers in association with tissues deposition of IgA
[14]. Moreover, ALD patients do not rarely have signs of
auto-immunity consisting in increased titers of circulating
antibodies directed against non-organ-speciﬁc and liver-
speciﬁc autoantigens [15]. In particular, antiphospholipid
antibodies can be observed in up to 80% of patients with
alcoholic hepatitis or cirrhosis, but are not infrequent in
heavy drinkers with milder liver damage [16, 17]. A further2 International Journal of Hepatology
evidence supporting the implication of adaptive immunity
in ALD comes from the recent demonstration that IL-17-
producing T helper (Th-17) lymphocytes are evident in
hepatic inﬂammatory inﬁltrates of patients with alcoholic
hepatitis/cirrhosis in concomitance with an increase in IL-17
plasma levels [18]. The implication of Th-17 T-cells in ALD
is particularly important considering the increasing impor-
tance ascribed to these cells in the pathogenesis of several
chronicinﬂammatorydiseasesincludingviralhepatitisBand
C and primary biliary cirrhosis [19].
2. Role of OxidativeStress in
Alcohol-Induced Immune Reactions
The mechanisms by which alcohol triggers adaptive immu-
nity are still incompletely characterized. Pioneering study
by Israel and colleagues [20] has shown that the adducts
originating from acetaldehyde binding to hepatic proteins
cause the production of speciﬁc antibodies when injected
into experimental animals. The presence of antiacetaldehyde
antibodies has been subsequently conﬁrmed in rats chroni-
c a l l ye x p o s e dt oa l c o h o la sw e l la si na l c o h o l i cp a t i e n t s[ 21,
22]. Guinea pig immunization with acetaldehyde-modiﬁed
hemoglobin followed by alcohol feeding reproduces several
features of alcoholic hepatitis [23]. However, the interest for
acetaldehyde-inducedimmuneresponsesishamperedbythe
uncertainty regarding identity of the antigens involved and
by the low speciﬁcity for ALD of anti-acetaldehyde antibod-
ies [24]. Subsequent studies demonstrate that another meta-
bolite of ethanol, that is, hydroxyethyl free radical (HER),
produced during cytochrome P4502E1- (CYP2E1-) depen-
dent ethanol oxidation, can interact with proteins generating
antigens distinct from those derived from acetaldehyde [25].
Anti-HER IgG are detectable in chronically ethanol-fed rats
as well as in alcohol abusers [26, 27]. Human anti-HER IgG
are recognized as main antigen HER-modiﬁed CYP2E1 [28],
and their presence strictly correlates with CYP2E1 activity
[29].
Oxidative stress is one of the feature of alcohol hepato-
toxicityandsigniﬁcantlycontributestoliverinjury[30].One
of the consequence of oxidative stress is the stimulation of
lipid peroxidation with the generation of wide array of re-
active lipid breakdown products including aldehydes such as
malondialdehyde (MDA), 4-hydroxynonenal (4-HNE), and
lipid hydroperoxides that are readily detectable in the serum
and the liver of ALD patients and alcohol-fed rodents [30].
Many lipid peroxidation products are highly reactive and
by interacting with cellular constituents generate antigenic
products that have been implicated in the stimulation
of immune responses associated with atherosclerosis and
several autoimmune diseases [31, 32]. We have observed
that a large proportion (55–70%) of the patients with ad-
vanced ALD (alcoholic hepatitis and/or cirrhosis), but not
heavy drinkers with fatty liver only, have elevated titers
of circulating IgG against proteins adducted by MDA, 4-
HNE, and oxidized arachidonic acid [33]. In about 35%
of these patients, the presence of anti-MDA antibodies is
associated with the detection of peripheral blood CD4+ T
cells responsive to MDA adducts, indicating the capability
of lipid oxidation antigens to trigger both the humoral and
cellular branches of adaptive immunity [34]. At present,
the chemical identity of the diﬀerent antigens involved is
still incompletely characterized. Studies by Tuma and Thiele
have shown that the reaction between MDA, acetaldehyde,
and lysine ε-amino groups generates condensation products
named malondialdehyde-acetaldehyde adducts (MAA) that
not only are highly immunogenic, but also can stimulate in-
ﬂammation [35]. MAA adducts have been detected in the
liver of ethanol-fed rats, and their formation is responsible
for the increased titers of IgG recognizing MAA-modiﬁed
proteins in patients with advanced ALD [36]. Considering
that appreciable amounts of acetaldehyde and MDA are
generated in the liver during alcohol intoxication, it is well
possible that MAA adducts might signiﬁcantly contribute
to immune response in ALD. It is noteworthy that rodents
and humans have circulating natural antibodies, mainly of
the IgM class, targeting oxidation-derived epitopes including
M D Aa n dM A Aa d d u c t s[ 37, 38]. These natural antibodies
display protective action against atherosclerosis by scaveng-
ing oxidized LDL and preventing inﬂammation [37]. In our
hands, the antibody responses observed in ALD patients
speciﬁcally involve only IgG, while IgM against MDA and
MAA adducts do not diﬀer from those in healthy controls
[33, 36]. This suggests that the extensive lipid peroxidation
caused by alcohol abuse might overcome the scavenging
capacity of natural IgM antibodies and, in combination with
inﬂammatory stimuli, favors the activation of B- and T-cell
clones recognizing a variety of oxidation-derived antigens.
Oxidative stress also likely accounts for the development
of ALD-associated antiphospholipid antibodies, since they
recognize as antigens oxidized phospholipids, namely, oxi-
dized cardiolipin and phosphatidylserine [39, 40]. Inter-
estingly, the presence of IgG targeting lipid-peroxidation-
derived antigens is evident in patients with chronic hepatitis
C (CHC) consuming moderate amounts of alcohol and
increases in a dose-dependent manner with alcohol intake
[41]. This is consistent with recent observations about the
synergicactionofethanolandhepatitisCvirusinpromoting
oxidative stress within the hepatocytes [42].
3. MechanismsPossibly Involvedin the
Recruitment of AdaptiveImmunityin
Alcoholic Liver Disease
It is known since long time that excessive alcohol consump-
tion aﬀects the innate and adaptive immunity increasing
the susceptibility to infections and compromising tissue res-
ponse to injury [5]. In particular, both acute and chronic
alcohol intakes depress antigen presentation by monocytes
and dendritic cells, aﬀect the expression costimulatory mole-
cules, and reduce T-cell proliferation [5]. It is possible that,
during the evolution of ALD, the production of proinﬂam-
matory cytokines/chemokines by Kupﬀer cells and NKT
lymphocytes might overcome alcohol-dependent immune
depression promoting the response of intraportal lymphoid
follicles to antigens derived from oxidatively damagedInternational Journal of Hepatology 3
hepatocytes. Alcohol-induced oxidative stress can specif-
ically facilitate this process through several mechanism.
In either rodents and humans, chronic alcohol exposure
increases the levels of circulating bioactive oxidized phos-
pholipids able to interact with plated activating factor (PAF)
receptors and to stimulate inﬂammation [43]. Further-
more, oxidized lipid and protein adducted by lipid peroxi-
dation end products act as danger-associated molecular
patterns (DAMPs) and are capable of activating inﬂamma-
tory and immune cells through the interaction with pattern
recognition receptors (PRRs) such as scavenger receptors
(SRA-1,2, CD36, SR-B1, and LOX-1) and toll-like receptors
(TLR-4) [44]. In particular, CD36 eﬃciently recognizes
free and protein-bound oxidized lipids favoring their inter-
nalization by macrophages and antigen-presenting cells
with their subsequent presentation to immune cells [44].
The interaction between CD36 and TLR-4 also promotes
proinﬂammatory activation of macrophages and vascular
endothelial cells in response to oxidation-speciﬁc epitopes
[44]. In the liver, the presentation of oxidative-stress-derived
antigens by hepatic stellate cells (HSCs) might represent an
additional pathway for CD4+ and CD8+ T-cell activation,
as human HSCs are eﬃcient professional antigen presenting
cells [45] and have the capacity to internalize oxidatively
modiﬁed proteins through CD36 [46]. According to this sce-
nario,timecourseexperimentsperformedinenteralalcohol-
fed rats show that the hepatic mRNAs expression of Th-
1 cytokines (TNF-α, IL-12) has a biphasic pattern peaking
after 14 days of alcohol feeding and then rising again after 35
days [47]. Oxidative stress is evident already after few days of
alcohol exposure, but lipid-peroxidation-derived antibodies
are evident in concomitance with the late increase cytokine
production [47] and their formation is prevented by the
antioxidant N-acetylcysteine [48]. Moreover, stimulation of
B cells through Toll-like receptor 9 (TLR-9) has been impli-
cated in causing hyperimmunoglobulinemia in patients with
alcoholic cirrhosis [49]. The immune responses in ALD
might be inﬂuenced by alterations of the immunoregulatory
mechanisms. Hepatic steatosis and oxidative stress lower re-
gulatory T-cells (Tregs) population in the liver [50]. This
might impact on B- and T-cell activation by oxidation-speci-
ﬁc epitopes, as, during the evolution of atherosclerosis, Tregs
impairment favors lymphocyte responses against oxidized
LDL [51]. Finally, further stimuli to adaptive immunity in
ALD might involve osteopontin and the adipokines leptin
and adiponectin. Osteopontin is a cytokine produced by
many cell types, including macrophages and T-lymphocytes,
that promotes macrophage and T-cell activation, stimulates
lymphocyte Th-1 and Th-17 diﬀerentiation, and induces B-
cell proliferation and antibody production [52, 53]. Increas-
ed osteopontin is a feature of several inﬂammatory and
autoimmune diseases, where it directs the recruitment of
autoreactive T cells and lymphocyte Th-1 and Th-17 diﬀer-
entiation [53]. An increased liver production of osteopontin
correlates with the extent of inﬂammation in alcohol-fed
rodents [54], while hepatic osteopontin mRNA expression
is higher in patients with alcoholic hepatitis than in heavy
drinkers with fatty liver only [55]. Leptin and adiponectin
originating from the adipose tissue have immunoregulatory
functions: leptin stimulates lymphocyte survival and prolif-
eration favoring Th-1 reactions, while adiponectin downreg-
ulates macrophage activity and B- and T-cells proliferation
[56]. Alcohol inﬂuences adipocyte production of adipokines
increasing serum leptin in patients with alcoholic liver
disease (ALD) [57] and lowering adiponectin secretion [58].
Little is known about the origin of antiphospholipid
antibodies often associated with ALD. In the recent years,
increasing evidence has linked defects in the disposal of
apoptotic cells with the development of antiphospholipid
antibodies [59, 60]. In particular, phagocytosis of apoptotic
bodies by immature dendritic cells in an inﬂammatory
context can lead to the presentation of apoptotic cell-derived
self-antigens to T-lymphocytes [59, 60]. We have observ-
ed that antiphospholipid antibodies from the sera of ALD
patients bind to apoptotic, but not to living cells, by speciﬁ-
cally targeting oxidized phosphatidylserine expressed on the
cell surface [40]. This is consistent with the detection of
oxidized phosphatidylserine on surface of apoptotic bodies
[61] and suggests that ALD-associated antiphospholipid
antibodies may originate from alterations in the disposal
of apoptotic hepatocytes. Indeed, growing evidence points
to the importance of apoptosis-derived antigens as targets
of antiphospholipid antibodies [62]. Hepatocyte apoptosis
is one of the consequence of chronic alcohol intake [30],
and an increase in apoptotic bodies is well evident in liver
biopsies of ALD patients [63]. At the same time, alcohol
impairs the capacity of neighboring hepatocytes to dispose
apoptoticcellsthroughasialoglycoproteinreceptor-mediated
phagocytosis [64] and primes Kupﬀer cells to produce TNF-
α and IL-6 when exposed to apoptotic bodies [65].
The presence of both non-organ-speciﬁc and liver-
speciﬁc autoantibodies is a common feature in ALD. Among
these latter, we have reported that alcohol-fed rats as well
as about 40% of the patients with advanced ALD develop
circulating IgG directed against CYP2E1 [66, 67]. Anti-
CYP2E1 autoantibodies from ALD patients are similar to
those associated with halothane hepatitis and recognize at
least two distinct conformational epitopes on the molecule
surface, in a position compatible with the targeting of
CYP2E1 present on the outer layer of the hepatocyte plasma
membranes [68]. The development of anti-cytochrome P450
(CYP) isoenzymes is rather common in liver diseases such
astype-2autoimmunehepatitis,drug-inducedhepatitis,and
hepatitis C [69]. In drug-induced hepatitis, it has been
postulated that the binding of reactive metabolites to CYPs
promotesbothhumoralimmuneresponsesagainstthedrug-
derivedepitope(s)and,atthesametime,favorstheactivation
of normally quiescent autoreactive lymphocytes recognizing
the native CYP molecules [69]. ALD patients with anti-HER
antibodies have a 4-fold increased risk of developing anti-
CYP2E1 autoreactivity as compared to patients without anti-
HER IgG [67]. This indicates that CYP2E1 alkylation by
HER is involved in the development of ALD anti-CYP2E1
autoantibodies. Nonetheless, additional factors might favor
the breaking of self-tolerance in ALD. We have observed that
ap o l y m o r p h i s m( T h r
17→Ala substitution) in the cytotoxic-
T-lymphocyte-associated antigen-4 (CTLA-4) gene increases
by 3.8-fold the risk of developing anti-CYP2E1 IgG without4 International Journal of Hepatology
inﬂuencing the formation of anti-HER antibodies [67]. ALD
patients having both anti-HER IgG and mutated CTLA-
4 show a prevalence of anti-CYP2E1 autoreactivity 23-fold
higher than those negative for both these factors [67].
CTLA-4 is a membrane receptor expressed by activated T-
lymphocytesandbyCD25+ CD4+ Tregsthatdownmodulates
T-cell-mediated responses to antigens [70]. Accordingly, in
humans, CTLA-4 genetic polymorphisms are risk factors for
several autoimmune diseases, including primary biliary cir-
rhosis and type-1 autoimmune hepatitis [71]. More recently,
Thiele and coworkers have shown that mice immunization
with MAA-modiﬁed liver cytosolic proteins in the absence
of adjuvants is able to promote autoimmune injury in the
liver [72]. This indicates that, in some ALD patients, the
combination of CYP2E1 modiﬁcation by HERs, impaired
CTLA-4 control of T-cell proliferation, and the stimulation
of immune system by lipid peroxidation products can lead
to the breaking of self-tolerance. Preliminary data shows that
high titers of anti-CYP2E1 autoantibodies correlate with the
extension of lymphocyte inﬁltration and the frequency of
apoptotic hepatocytes, suggesting that in a subset of ALD
autoimmune mechanisms might contribute to tissue injury.
4.Possible Role ofAdaptiveImmunity
in the Progressionof Alcohol Liver Damage
So far little is known about the mechanisms by which adap-
tive immunity might contribute to hepatic inﬂammation in
ALD. However, data emerging from experimental models
of atherosclerosis indicate that IFN-γ,T N F - α, and CD40
ligand (CD154) produced by Th-1 CD4+ T-cell responsive
to antigens in oxidized LDL drive plaque macrophages to
produce reactive oxygen species, NO, and proinﬂamma-
tory cyto/chemokines [73]. Studies in alcohol-fed rodents
show that the development of antibodies against lipid-
peroxidation-derived epitopes associate with the hepatic
expression of proinﬂammatory cytokines and histological
evidenceofsteatohepatitis [47,48].Inhumans,aprospective
survey has evidenced an association between the presence
of antibodies toward alcohol-modiﬁed hepatocytes and an
increased risk of developing alcoholic liver cirrhosis [74].
On the same line, heavy drinkers with lipid-peroxidation-
derivedantibodieshavea5-foldhigherprevalenceofelevated
plasma TNF-α levels than alcohol abusers with these anti-
bodies within the control range [75]. Moreover, in these
subjects, the combination of high TNF-α and lipid-per-
oxidation-induced antibodies increases by 11-fold the risk of
developing advanced ALD [75]. Interestingly, the combina-
tion of steatosis and high titers of antibodies against lipid-
peroxidation-derived adducts is an independent predictor
of advanced ﬁbrosis/cirrhosis in alcohol-consuming patients
with chronic hepatitis C [76]. Further evidence in favor of a
possiblecontributionofoxidative-stress-mediatedimmunity
in sustaining hepatic inﬂammation comes from studies in
nonalcoholic steatohepatitis (NASH). We have observed that
antibodies against lipid-peroxidation-derived antigens simi-
lar to those detected in ALD, are present in rodent models of
NASH [77] as well as in about 40% of adult NAFLD/NASH
patients [78] and in 60% of children with NASH [79].
Experiments comparing the development of NASH induced
by mice feeding with a methionine/choline deﬁcient (MCD)
diet demonstrate that C57BL/6, but not BALB/C, mice
have an increased prevalence of liver inﬁltrating T and B
cells and generate antibodies against MDA adducts. Hepatic
necroinﬂammation and the expression of TNF-α and IL-12
are signiﬁcantly higher in C57BL/6 mice than in BALB/C
mice. Among MCD-treated mice, a signiﬁcant positive
correlation is also evident between the titers of anti-MDA
antibodies and the number of hepatic necroinﬂammatory
foci [80]. In line with these ﬁndings, in children with
NAFLD, high titers of anti-MDA adduct IgG, but not of
other oxidative stress markers, are associated with more
severe lobular inﬂammation and with 13-fold increased
risk of overt steatohepatitis [79]. We have observed that in
mice with NASH, anti-MDA IgG target speciﬁc antigens in
hepatic necroinﬂammatory foci leading to the formation
of immunocomplexes. Furthermore, Rensen and coworkers
have detected extensive deposition of diﬀerent complement
fractions in liver biopsies form NASH patients that associates
with increased hepatocyte apoptosis, granulocyte inﬁltration
and higher liver expression of IL-1β,I L - 6 ,a n dI L - 8m R N A s
[81].Thissuggeststhepossibilitythatcomplementactivation
might bridge adaptive and innate immune responses during
ALD evolution. Supporting this view, recent observations by
Nagy’sgroupdemonstratecomplementactivationwithinthe
liver of alcohol-fed mice that leads to increased production
of C3a anaphylatoxin [82]. Moreover, mice deﬁcient of C3
and C5 are protected against hepatic injury, while the lack of
the complement-regulating protein CD55/DAF exacerbates
alcohol hepatotoxicity [82].
5. Conclusion andFuturePerspectives
In conclusion, data so far obtained indicates that alcohol-
induced oxidative modiﬁcations of hepatic constituents
trigger speciﬁc immune responses and, in some conditions,
may favor the breaking of the self-tolerance toward liver con-
stituents. The development of adaptive immune responses
is likely favored by the capacity of alcohol to stimulate by
diﬀerentwaysinnateimmunity[4–8].Althoughstillindirect,
available evidence also suggests that the development of
humoral and cellular immunity may contribute to hepatic
inﬂammation during the evolution of ALD. Nonetheless,
during the progression of ALD to cirrhosis, additional
mechanisms may be at work. Recent data indicate that the
interactions between myoﬁbroblast-like hepatic stellate cells
(HSC/MFs), Kupﬀer cells, and CD4+ T-lymphocytes are cri-
tical for the regulation of ﬁbrogenic responses [83, 84]. In
particular, by expressing adhesion molecules (VCAM-1 and
ICAM-1) and chemokines (CCL2, CXCL9/10, CXCL16, and
fractalin), HSC/MFs are essential for the liver recruitment
of lymphocytes and provide the milieu for their survival
and activation [84]. On the other hand, Th-2 cytokines
(IL-4 and IL-13) from CD4+ T cells directly sustain matrix
deposition by HSC/MFs and favor “alternative” M2 activa-
tion of macrophages with the production of chemokinesInternational Journal of Hepatology 5
(CCL6 and CCL17), IL-10, TGF-β, and VEGFs that drive
healing responses and angiogenesis [83, 84]. At present, it
is not known whether T-cell stimulation by oxidative-stress-
derived antigens might promote Th-2 lymphocyte develop-
ment and M2 macrophage polarization, contributing to
ﬁbrogenesis.
From the clinical point of view, prospective studies are
required to dissect out the precise role of immune responses
in the progression of human ALD. If supported by further
data,theconceptthatadaptiveimmunityhasaroleinalcohol
hepatotoxicity might lead to the development of simple im-
munometric assays to discriminate ALD patients at risk of
progressing to hepatitis and/or ﬁbrosis and moreover, the
identiﬁcation of alcohol abusers with a prominent immune
or autoimmune component in their hepatic disease that
might lead to a targeted use of immune-suppressive therapy
in ALD.
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